Chicken embryo as animal model to study drug distribution to the developing brain

Zosen, Denis; Hadera, Mussie Ghezu; Lumor, Josephine Sena; Andersen, Jannike Mørch; Paulsen, Ragnhild E.

doi:10.1016/j.vascn.2021.107105

Cited by 21 publications

(13 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the case of complex and organ-specific enzymatic metabolism, a correct evaluation of the compound metabolic activation should be carefully investigated, and an alternative route of administration other than topical could be used. Intravenous or intra-allantois injection of compound could represent a correct and feasible alternative [ 63 , 64 ].…”

Section: Discussionmentioning

confidence: 99%

A Face-To-Face Comparison of Tumor Chicken Chorioallantoic Membrane (TCAM) In Ovo with Murine Models for Early Evaluation of Cancer Therapy and Early Drug Toxicity

Rupp

Legrand

Hunault

et al. 2022

Cancers

View full text Add to dashboard Cite

Ethical considerations, cost, and time constraints have highlighted the need to develop alternatives to rodent in vivo models for evaluating drug candidates for cancer. The tumor chicken chorioallantoic membrane (TCAM) model provides an affordable and fast assay that permits direct visualization of tumor progression. Tumors from multiple species including rodents and human cell lines can be engrafted. In this study, we engrafted several tumor models onto the CAM and demonstrated that the TCAM model is an alternative to mouse models for preliminary cancer drug efficacy testing and toxicity analysis. Tumor cells were deposited onto CAM, and then grown for up to an additional 10 days before chronic treatments were administered. The drug response of anticancer therapies was screened in 12 tumor cell lines including glioblastoma, melanoma, breast, prostate, colorectal, liver, and lung cancer. Tumor-bearing eggs and tumor-bearing mice had a similar chemotherapy response (cisplatin and temozolomide) in four human and mouse tumor models. We also demonstrated that lethality observed in chicken embryos following chemotherapies such as cisplatin and cyclophosphamide were associated with corresponding side-effects in mice with body weight loss. According to our work, TCAM represents a relevant alternative model to mice in early preclinical oncology screening, providing insights for both the efficacy and the toxicity of anticancer drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

A Face-To-Face Comparison of Tumor Chicken Chorioallantoic Membrane (TCAM) In Ovo with Murine Models for Early Evaluation of Cancer Therapy and Early Drug Toxicity

Rupp

Legrand

Hunault

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Avians are an exquisite model for pharmacological testing due to in ovo embryonic accessibly, low cost and an abundant number of embryos ( Hebert et al, 2005 ; Hodges, 1946 ; Karnofsky and Lacon, 1964 ; Kue et al, 2015 ; Robel, 1993 ; Vidal, 1953 ; Zosen et al, 2021 ), despite drug efficacy and metabolism being distinct from those in mammals. Several drugs currently used in preclinical cancer trials or treatments were initially tested on avian embryos ( Bueker and Platner, 1956 ; Karnofsky and Lacon, 1964 ; Kue et al, 2015 ; Ryley, 1968 ; Zuniga et al, 2003 ).…”

Section: Discussionmentioning

confidence: 99%

Pharmacological intervention of the FGF–PTH axis as a potential therapeutic for craniofacial ciliopathies

Paese

Chang

Kristeková

et al. 2022

Disease Models &Amp; Mechanisms

View full text Add to dashboard Cite

Ciliopathies represent a disease class characterized by a broad range of phenotypes including polycystic kidneys and skeletal anomalies. Ciliopathic skeletal phenotypes are among the most common and most difficult to treat due to a poor understanding of the pathological mechanisms leading to disease. Using an avian model (talpid2) for a human ciliopathy with both kidney and skeletal anomalies (Orofaciodigital syndrome 14), we identified disruptions in the FGF23-PTH axis that resulted in reduced calcium uptake in the developing mandible and subsequent micrognathia. While pharmacological intervention with the FDA-approved pan-FGFR inhibitor AZD4547 alone rescued expression of the FGF target Sprouty2, it did not significantly rescue micrognathia. In contrast, treatment with a cocktail of AZD4547 and Teriparatide acetate, a PTH agonist and FDA-approved treatment for osteoporosis, resulted in a molecular, cellular, and phenotypic rescue of ciliopathic micrognathia in talpid2 mutants. Together, these data provide novel insight into pathological molecular mechanisms associated with ciliopathic skeletal phenotypes and a potential therapeutic strategy for a pleiotropic disease class with limited to no treatment options.

show abstract

“…Avians are an exquisite model for pharmacological testing due to in ovo embryonic accessibly, low cost, and an abundant number of embryos (Zosen et al, 2021). Several drugs currently used in preclinical cancer trials or treatments were initially tested on avian embryos (Bueker and Platner, 1956; Karnofsky and Lacon, 1964; Kue et al, 2015; Ryley, 1968; Zuniga et al, 2003).…”

Section: Discussionmentioning

confidence: 99%

Pharmacological intervention of the FGF-PTH axis as a potential therapeutic for craniofacial ciliopathies

Paese

Chang

Kristeková

et al. 2022

Preprint

View full text Add to dashboard Cite

Ciliopathies represent a disease class characterized by a broad range of phenotypes including polycystic kidneys and skeletal anomalies. Ciliopathic skeletal phenotypes are among the most common and most difficult to treat due to a poor understanding of the pathological mechanisms leading to disease. Using an avian model (talpid2) for a human ciliopathy with skeletal anomalies (Orofaciodigital syndrome 14), we identified disruptions in the FGF23-PTH axis that resulted in reduced calcium uptake in the developing mandible and subsequent micrognathia. While pharmacological intervention with the FDA-approved pan-FGFR inhibitor AZD4547 alone rescued expression of the FGF target Sprouty2, it did not significantly rescue micrognathia. In contrast, treatment with a cocktail of AZD4547 and Teriparatide acetate, a PTH agonist and FDA-approved treatment for osteoporosis, resulted in a molecular, cellular, and phenotypic rescue of ciliopathic micrognathia in talpid2 mutants. Together, these data provide novel insight into pathological molecular mechanisms associated with ciliopathic skeletal phenotypes and a potential therapeutic strategy for a pleiotropic disease class with limited to no treatment options.Summary StatementTreatment options for ciliopathic phenotypes are very limited. Using an avian model, we report a novel molecular mechanism and potential therapeutic treatment for ciliopathic micrognathia.

show abstract

Chicken embryo as animal model to study drug distribution to the developing brain

Cited by 21 publications

References 24 publications

A Face-To-Face Comparison of Tumor Chicken Chorioallantoic Membrane (TCAM) In Ovo with Murine Models for Early Evaluation of Cancer Therapy and Early Drug Toxicity

A Face-To-Face Comparison of Tumor Chicken Chorioallantoic Membrane (TCAM) In Ovo with Murine Models for Early Evaluation of Cancer Therapy and Early Drug Toxicity

Pharmacological intervention of the FGF–PTH axis as a potential therapeutic for craniofacial ciliopathies

Pharmacological intervention of the FGF-PTH axis as a potential therapeutic for craniofacial ciliopathies

Contact Info

Product

Resources

About